UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

Leukemia, 2013-02, Vol.27 (2), p.430-440

2013

Volltextzugriff (PDF)

The skinny on obesity and plasma cell myeloma: a review of the literature

Bone marrow transplantation (Basingstoke), 2014-08, Vol.49 (8), p.1009-1015

2014

Volltextzugriff (PDF)

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

Bone marrow transplantation (Basingstoke), 2009-05, Vol.43 (10), p.793-800

2009

Volltextzugriff (PDF)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

Leukemia, 2017-07, Vol.31 (7), p.1648-1650

2017

Volltextzugriff (PDF)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

HemaSphere, 2022-06, Vol.6 (Suppl), p.839-840

2022

Volltextzugriff (PDF)

An Activated Receptor Tyrosine Kinase, TEL/PDGFβR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice

Proceedings of the National Academy of Sciences - PNAS, 2003-08, Vol.100 (16), p.9506-9511

2003

Volltextzugriff (PDF)

A Murine Model of CML Blast Crisis Induced by Cooperation between BCR/ABL and NUP98/HOXA9

Proceedings of the National Academy of Sciences - PNAS, 2002-05, Vol.99 (11), p.7622-7627

2002

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S195-S196

2021

Volltextzugriff (PDF)

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

The EMBO journal, 1998-09, Vol.17 (18), p.5321-5333

1998

Volltextzugriff (PDF)

The TEL/Platelet-Derived Growth Factor β Receptor (PDGFβ R) Fusion in Chronic Myelomonocytic Leukemia is a Transforming Protein that Self-Associates and Activates PDGFβ R Kinase-Dependent Signaling Pathways

Proceedings of the National Academy of Sciences - PNAS, 1996-12, Vol.93 (25), p.14845-14850

1996

Volltextzugriff (PDF)

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

The Journal of clinical investigation, 2010-06, Vol.120 (6), p.2109-2118

2010

Volltextzugriff (PDF)

Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3

Blood, 2001-03, Vol.97 (5), p.1435-1441

2001

Volltextzugriff (PDF)

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL

Blood, 2001-03, Vol.97 (5), p.1442-1450

2001

Volltextzugriff (PDF)

Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression

Journal of Virology, 1999-01, Vol.73 (1), p.728-737

1999

Volltextzugriff (PDF)

c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations

Blood, 2005-10, Vol.106 (7), p.2452-2461

2005

Volltextzugriff (PDF)

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3

Hematology, Transfusion and Cell Therapy, 2022-10, Vol.44, p.S245-S246

2022

Volltextzugriff (PDF)

TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

Blood, 1999-03, Vol.93 (5), p.1707-1714

1999

Volltextzugriff (PDF)

A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7548-7548

2006

Volltextzugriff (PDF)

Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma

Clinical lymphoma & myeloma, 2007-11, Vol.7 (9), p.587-589

2007

Volltextzugriff (PDF)

Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581

The Journal of clinical investigation, 2000-02, Vol.105 (4), p.423-432

2000

Volltextzugriff (PDF)

The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways

Blood, 2001-12, Vol.98 (12), p.3390-3397

2001

Volltextzugriff (PDF)

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

Haematologica (Roma), 2006-11, Vol.91 (11), p.1581

2006

Volltextzugriff (PDF)

Complete remission of TEL-PDGFRB–induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657

Blood, 2004-07, Vol.104 (2), p.561-564

2004

Volltextzugriff (PDF)

TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor

Blood, 1999-03, Vol.93 (5), p.1707-1714

1999

Volltextzugriff (PDF)

Platelet and osteoclast beta sub(3) integrins are critical for bone metastasis

Proceedings of the National Academy of Sciences - PNAS, 2003-11, Vol.100 (24), p.14205-14210

2003

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(58)
Humans
(49)
Female
(26)
Male
(25)
Adult
(23)
Animals
(21)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Hematology
(20)
Mice
(19)
Middle Aged
(19)
Aged
(16)
Oncology
(15)
Multiple Myeloma
(14)
Bone Marrow
(13)
Mutation
(13)
Hematologic And Hematopoietic Diseases
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Risk Factors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

The skinny on obesity and plasma cell myeloma: a review of the literature

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

An Activated Receptor Tyrosine Kinase, TEL/PDGFβR, Cooperates with AML1/ETO to Induce Acute Myeloid Leukemia in Mice

A Murine Model of CML Blast Crisis Induced by Cooperation between BCR/ABL and NUP98/HOXA9

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

The TEL/Platelet-Derived Growth Factor β Receptor (PDGFβ R) Fusion in Chronic Myelomonocytic Leukemia is a Transforming Protein that Self-Associates and Activates PDGFβ R Kinase-Dependent Signaling Pathways

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL

Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression

c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3

TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM)

Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma

Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581

The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma

Complete remission of TEL-PDGFRB–induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657

TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor

Platelet and osteoclast beta sub(3) integrins are critical for bone metastasis

Suchergebnisse filtern